Schonfeld Strategic Advisors LLC Takes Position in Apogee Therapeutics, Inc. (NASDAQ:APGE)

Schonfeld Strategic Advisors LLC acquired a new stake in Apogee Therapeutics, Inc. (NASDAQ:APGE) during the 4th quarter, HoldingsChannel.com reports. The fund acquired 70,766 shares of the company’s stock, valued at approximately $3,206,000.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of the company. China Universal Asset Management Co. Ltd. raised its stake in Apogee Therapeutics by 10.3% during the 4th quarter. China Universal Asset Management Co. Ltd. now owns 9,547 shares of the company’s stock valued at $432,000 after acquiring an additional 892 shares in the last quarter. Arizona State Retirement System raised its stake in shares of Apogee Therapeutics by 17.3% during the fourth quarter. Arizona State Retirement System now owns 6,517 shares of the company’s stock valued at $295,000 after purchasing an additional 960 shares in the last quarter. New York State Common Retirement Fund lifted its holdings in Apogee Therapeutics by 8.9% in the fourth quarter. New York State Common Retirement Fund now owns 12,187 shares of the company’s stock worth $552,000 after purchasing an additional 1,000 shares during the period. JPMorgan Chase & Co. lifted its holdings in Apogee Therapeutics by 4.3% in the third quarter. JPMorgan Chase & Co. now owns 29,555 shares of the company’s stock worth $1,736,000 after purchasing an additional 1,212 shares during the period. Finally, Rhumbline Advisers grew its position in Apogee Therapeutics by 3.4% in the 4th quarter. Rhumbline Advisers now owns 52,720 shares of the company’s stock valued at $2,388,000 after buying an additional 1,750 shares in the last quarter. 79.04% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of research analysts recently commented on the stock. Wedbush reiterated an “outperform” rating and set a $90.00 price objective on shares of Apogee Therapeutics in a research note on Tuesday, March 11th. Guggenheim reissued a “buy” rating on shares of Apogee Therapeutics in a research note on Monday, February 10th. Finally, Citigroup assumed coverage on Apogee Therapeutics in a report on Thursday, March 13th. They issued a “buy” rating and a $95.00 price objective for the company. Six equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, Apogee Therapeutics has an average rating of “Buy” and a consensus price target of $92.17.

Insiders Place Their Bets

In other news, CEO Michael Thomas Henderson sold 15,000 shares of the firm’s stock in a transaction that occurred on Wednesday, February 5th. The shares were sold at an average price of $40.58, for a total transaction of $608,700.00. Following the completion of the sale, the chief executive officer now owns 1,302,987 shares of the company’s stock, valued at approximately $52,875,212.46. This trade represents a 1.14 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, insider Carl Dambkowski sold 1,590 shares of the firm’s stock in a transaction on Wednesday, March 5th. The shares were sold at an average price of $30.48, for a total value of $48,463.20. Following the sale, the insider now directly owns 251,033 shares of the company’s stock, valued at $7,651,485.84. This represents a 0.63 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 33,970 shares of company stock worth $1,241,701 over the last 90 days. Corporate insiders own 36.10% of the company’s stock.

Apogee Therapeutics Stock Up 2.3 %

NASDAQ:APGE opened at $40.12 on Friday. The company’s 50 day moving average is $35.65 and its 200-day moving average is $42.14. Apogee Therapeutics, Inc. has a 12 month low of $26.20 and a 12 month high of $63.50. The firm has a market cap of $1.80 billion, a price-to-earnings ratio of -16.58 and a beta of 1.70.

Apogee Therapeutics (NASDAQ:APGE) last posted its quarterly earnings data on Monday, March 3rd. The company reported ($1.19) earnings per share for the quarter, missing the consensus estimate of ($0.94) by ($0.25). Research analysts predict that Apogee Therapeutics, Inc. will post -3.09 EPS for the current fiscal year.

About Apogee Therapeutics

Apogee Therapeutics, Inc, through its subsidiary, operates as a biotechnology company that develops biologics for the treatment of atopic dermatitis (AD), asthma, chronic obstructive pulmonary disease (COPD), and related inflammatory and immunology indications. The company primarily develops APG777, a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) for AD; and APG808, an SQ extended half-life mAb for COPD.